CULLINAN THERAPEUTICS, INC.
Income Statement
| Line Item | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $18.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $21.3M | $19.7M | $26.4M | $24.5M | $20.9M | $12.7M | $11.8M | $12.4M |
| SG&A Expense | $11.3M | $10.1M | $10.7M | $8.1M | $13.5M | $5.7M | $4.8M | $5.2M |
| Operating Income | $-32.6M | $-29.8M | $239.7M | $-32.7M | $-34.3M | $-18.4M | $-16.6M | $1.4M |
| Operating Margin | — | — | — | — | — | — | — | 7.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-28.9M | $-27.4M | $240.1M | $-32.5M | $-34.2M | $-18.3M | $-16.4M | $1.4M |
| Income Tax Expense | $-1.9M | $-2.5M | $66.1M | $-19.6M | $0 | $0 | $0 | $0 |
| Net Income | $-26.8M | $-24.8M | $174.9M | $-12.1M | $-32.5M | $-17.4M | $-15.6M | $-70.0K |
| Net Margin | — | — | — | — | — | — | — | -0.4% |
| EPS (Basic) | $-0.63 | $-0.54 | $3.90 | $-0.27 | $-0.76 | $-0.40 | $-0.36 | $0.00 |
| EPS (Diluted) | $-0.58 | $-0.54 | $3.77 | $-0.27 | $-0.76 | $-0.40 | $-0.36 | $0.00 |
| Shares Outstanding (Basic) | 45.2M | 45.6M | 44.9M | 44.4M | 44.3M | 43.4M | 43.3M | 43.5M |
| Shares Outstanding (Diluted) | 46.6M | 45.6M | 46.4M | 44.4M | 44.3M | 43.4M | 43.3M | 43.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |